156
Participants
Start Date
November 24, 2023
Primary Completion Date
August 31, 2025
Study Completion Date
January 31, 2027
Bedaquiline
Daily therapy for 12 weeks
Clofazimine
Daily therapy for 12 weeks
Pyrazinamide
Daily therapy for 12 weeks
Delamanid
Daily therapy for 12 weeks
Rifampin
Daily therapy for 26 weeks
Isoniazid
Daily therapy for 26 weeks
Ethambutol
Daily therapy for 8 weeks
Pyrazinamide
Daily therapy for 8 weeks
RECRUITING
GHESKIO, Port-au-Prince
RECRUITING
University of Cape Town, Cape Town
University of Cape Town
OTHER
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
OTHER
University of Stellenbosch
OTHER
University of California, Los Angeles
OTHER
Harvard School of Public Health (HSPH)
OTHER
Brigham and Women's Hospital
OTHER